Purinergic signalling: Therapeutic potential

Anales de la Real Academia Nacional de Farmacia

Volumn 71, Issue 2, 2005, Pages 283-319

  Burnstock, Geoffrey ^a  

^a Real Academia Nacional de Farmacia   (Spain)

Author keywords

Cancer; Cystic fibrosis; Interstitial cystitis; Kidney failure; Osteoporosis; Parkinson's disease; Peripheral vascular disease; Purinoceptors; Thrombosis; Visceral pain

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CLOPIDOGREL; CYCLOSPORIN; DIADENOSINE TETRAPHOSPHATE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; LETEPRINIM; MAGNESIUM CHLORIDE; MEPACRINE; NEUROLEPTIC AGENT; PENTIFYLLINE; PURINE NUCLEOSIDE; PURINE NUCLEOTIDE; PURINE P2Y RECEPTOR; PURINE RECEPTOR; PURINERGIC RECEPTOR AFFECTING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; SURAMIN; TICLOPIDINE; UNINDEXED DRUG; URIDINE TRIPHOSPHATE; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ALZHEIMER DISEASE; CANCER; CELL DEATH; CELL PROLIFERATION; CELL REGENERATION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; DRY EYE; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INTERSTITIAL CYSTITIS; LUNG DISEASE; NEPHROTOXICITY; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OSTEOPOROSIS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; REVIEW; RHEUMATIC DISEASE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STROKE; SUPRAVENTRICULAR TACHYCARDIA; URINARY TRACT OBSTRUCTION; VASCULAR DISEASE; VASODILATATION;

EID: 27844551677     PISSN: None     EISSN: 1697428X     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. BURNSTOCK, G. AND KNIGHT, G. E. (2004): Int. Rev. Cytol 240: 31-304.
2. RALEVIC, V. AND BURNSTOCK, G. (1998): Pharmacol Rev. 50: 413-492.
3. BURNSTOCK, G. (2002): Clinical Medicine 2: 45-53.
4. AGTERESCH, H. J.; DAGNELIE, P. C.; VAN DER BERG, J. W. O. AND WILSON, J. H. (1999): Drugs 58: 211-232.
5. BURNSTOCK, G. (2002): Arteriosclerosis, Thrombosis and Vascular Biology 22: 364-373.
6. YANG, A.; SONIN, D.; JONES, L.; BARRY, W. H. AND LIANG, B. T. (2004): Am. J. Physiol 287: H1096-H1103.
7. DI, V. F. AND SOLINI, A. (2002): Br. J. Pharmacol. 135:831-842.
8. GREIG, A. V. H.; LINGE, C.; TERENGHI, G.; MCGROUTHER, D. A. AND BURNSTOCK, G. (2003): J. Invest. Dermatol. 120: 1007-1015.
9. BURNSTOCK, G. (2001): Purinergic signalling in gut. In Abbracchio, M. P. and Williams, M. editors. Handbook of Experimental Pharmacology, Volume 151/ II. Purinergic and Pyrimidinergic Signalling II-Cardiovascular, Respiratory, Immune, Metabolic and Gastrointestinal Tract Function, Springer-Verlag, Berlin, pp. 141-238.
10. WYNN, G.; BEI, M.; RUAN, H-Z. AND BURNSTOCK, G. (2004): Am. J. Physiol Gastrointest Liver Physiol 287: G647-G657.
11. GALLICAN, J. J. (2004): Br. J. Pharmacol. 141: 1294-1302.
12. BURNSTOCK, G. (2001): Trends Pharmacol. Sci. 22: 182-188.
13. DI VIRGILIO, F.; FALZONI, S.; MUTINI, C.; SANZ, J. M. AND CHIOZZI, P. (1998): Drug Dev. Res. 45: 207-213.
14. LAMMAS, D. A.; STOBER, C.; HARVEY, C. J.; KENDRICK, N.; PANCHALINGAM, S. AND KUMARARATNE, D. S. (1997): Immunity. 7: 433-444.
15. LEMAIRE, I. AND LEDUC, N. (2004): Drug Dev. Res. 59: 118-127.
16. WAEBER, C. AND MOSKOWITZ, M. A. (2003): Neurology 61: S9-20.
17. HOEBERTZ, A.; ARNETT, T. R. AND BURNSTOCK, G. (2003): Trends Pharmacol. Sci. 24: 290-297.
18. KORCOK, J.; RAIMUNDO, L. N.; KE, H. Z.; SIMS, S. M. AND DIXON, S. J. (2004): J. Bone Miner. Res. 19: 642-651.
19. DELL'ANTONIO, G.; QUATTRINI, A.; CIN, E. D.; FULGENZI, A. AND FERRERO, M. E. (2002): Artritis Rheum 46: 3378-3385.
20. RYTEN, M., YANG, S. Y., DUNN, P. M., GOLDSPINK, G., AND BURNSTOCK, G. (2004): FASEB J. 18: 1404-1406.
21. UNWIN, R. J., BAILEY, M. A., AND BURNSTOCK, G. (2003): News Physiol. Sci. 0 18: 237-241.
22. VONEND, O., TURNER, C., CHAN, C. M., LOESCH, A., DELL'ANNA, G. C., SRAI, S. K., BURNSTOCK, G., AND UNWIN, R. (2004): Kidney Int. 66: 157-166.
23. BURNSTOCK, G. (2003): Purinergic receptors in the nervous system. In Schwiebert, E. M., editor. Current Topics in Membranes, Vol. 54. Purinergic Receptors and Signalling, Academic Press, San Diego, pp. 307-368.
24. FUJII, S., KATO, H., AND KURODA, Y. (2002): Neuroscience 113: 617-628.
25. OGATA, T., CHUAI, M., MORINO, T., YAMAMOTO, H., NAKAMURA, Y., AND SCHUBERT, P. (2003): Brain Res. 981: 174-183.
26. TSUDA, M., SHIGEMOTO-MOGAMI, Y., KOIZUMI, S., MIZOKOSHI, A., KOHSAKA, S., SALTER, M. W., AND INOUE, K. (2003): Nature 424: 778-783.
27. ABRAHAM, E. H., SALIKHOVA, A. Y., AND RAPAPORT, E. (2003): Current Topics in Membranes 54: 415-452.
28. CALVERT, R. C., SHABBIR, M., BANKS, F., THOMPSON, C. S., MIKHAILIDIS, D. P., MORGAN, R., AND BURNSTOCK, G. (2004): Anticancer Research 24: 2853-2859.
29. WHITE, N., RYTEN, M., CLAYTON, E., BUTLER, P. AND BURNSTOCK, G. (2005): Cancer Letters (on-line).
30. GREIG, A. V. H., LINGE, C., HEALY, V., LIM, P., CLAYTON, E., RUSTIN, M. H., MCGROUTHER, D. A., AND BURNSTOCK, G. (2003): J. Invest. Dermatol. 121: 315-327.
31. BURNSTOCK, G. (1996): Lancet 347: 1604-1605.
32. VLASKOVSKA, M., KASAKOV, L., RONG, W., BODIN, P., BARDINI, M., COCKAYNE, D. A., FORD, A. P. D. W., AND BURNSTOCK, G. (2001): J. Neurosci. 21: 5670-5677.
33. RONG, W. AND BURNSTOCK, G. (2004): Neuropharmacology 47: 1093-1101.
34. MCGARAUGHTY, S., WISMER, C. T., ZHU, C. Z., MIKUSA, J., HONORE, P., CHU, K. L., LEE, C. H., FALTYNEK, C. R., AND JARVIS, M. F. (2003): Br. J. Pharmacol. 140: 1381-1388.
35. YERXA, B. R. (2001): Drug Dev. Res. 52: 196-201.
36. ADRIAENSEN, D. AND TIMMERMANS, J. P. (2004): Curr. Opin. Pharmacol. 4: 207-214.
37. PINTOR, J., PERAL, A., PELAEZ, T., CARRACEDO, G., BAUTISTA, A., AND HOYLE, C. H. (2003). Drug Dev. Res. 59: 136-145.
38. SUETA, T., PAKI, B., EVERETT, A. W., AND ROBERTSON, D. (2003): Hear. Res. 183: 97-108.
39. GAYLE, S. AND BURNSTOCK, G. (2004): Cell Tissue Res. (on-line).
40. BURNSTOCK, G. (2001): Purinergic signalling in lower urinary tract. In Abbracchio, M. P. and Williams, M., editors. Handbook of Experimental Pharmacology, Volume 151/I. Purinergic and Pyrimidinergic Signalling I - Molecular, Nervous and Urinogenitary System Function, Springer-Verlag, Berlin, pp. 423-515.
41. ANDERSSON, K. E. AND HEDLUND, P. (2002): Urology 60: 13-20.
42. GLASS, R., BARDINI, M., ROBSON, T., AND BURNSTOCK, G. (2001): Cells Tissues Org. 169: 377-387.